ENLV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Enlivex Ltd (ENLV) is not a strong buy for a beginner, long-term investor at the moment. The technical analysis shows a bearish trend, and the financial performance indicates significant losses. While the analyst rating is positive with a raised price target, there are no immediate positive catalysts or strong trading signals to justify an entry point now. It is better to hold off on investing until more favorable conditions arise.
The technical indicators suggest a bearish trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 47.715, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.879, with resistance at 0.982 and support at 0.776.
H.C. Wainwright analyst raised the price target to $20 from $13 and maintained a Buy rating, citing completed debt financing and resources for clinical development.
No recent news or significant trading trends from hedge funds or insiders. Financial performance is extremely poor, with a massive YoY drop in net income (-24115.71%) and EPS (-4517.39%).
In Q4 2025, the company reported no revenue growth (0% YoY), a significant drop in net income (-24115.71% YoY), and a sharp decline in EPS (-4517.39% YoY). Gross margin remained at 0%.
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target to $20 from $13 and maintained a Buy rating, citing completed debt financing and resources for clinical development.
